BioCryst Pharmaceuticals, Inc.
BCRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,554,354 | $1,151,266 | $2,134,224 | $2,480,770 |
| - Cash | $104,713 | $110,643 | $304,767 | $504,389 |
| + Debt | $841,418 | $848,713 | $741,452 | $593,238 |
| Enterprise Value | $2,291,059 | $1,889,336 | $2,570,909 | $2,569,619 |
| Revenue | $450,712 | $331,412 | $270,827 | $157,170 |
| % Growth | 36% | 22.4% | 72.3% | – |
| Gross Profit | $438,227 | $326,751 | $264,233 | $149,906 |
| % Margin | 97.2% | 98.6% | 97.6% | 95.4% |
| EBITDA | $12,808 | -$116,335 | -$143,854 | -$121,738 |
| % Margin | 2.8% | -35.1% | -53.1% | -77.5% |
| Net Income | -$88,881 | -$226,539 | -$247,116 | -$184,062 |
| % Margin | -19.7% | -68.4% | -91.2% | -117.1% |
| EPS Diluted | -0.43 | -1.18 | -1.33 | -1.03 |
| % Growth | 63.6% | 11.3% | -29.1% | – |
| Operating Cash Flow | -$52,020 | -$95,141 | -$161,850 | -$142,157 |
| Capital Expenditures | -$1,124 | -$2,168 | -$1,351 | -$2,385 |
| Free Cash Flow | -$53,144 | -$97,309 | -$163,201 | -$144,542 |